|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 2/01/17 Sanofi 6-K 2/01/17 4:127K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 6-K Report by a Foreign Private Issuer HTML 13K 2: EX-99.1 Miscellaneous Exhibit HTML 14K 3: EX-99.2 Miscellaneous Exhibit HTML 7K 4: EX-99.3 Miscellaneous Exhibit HTML 25K
| 6-K |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2017
Commission File Number: 001-31368
SANOFI
(Translation of registrant’s name into English)
54, rue La Boétie, 75008 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
In January and February 2017, Sanofi issued the press releases attached hereto as Exhibit 99.1, 99.2 and 99.3 which is incorporated herein by reference.
Exhibit List
| Exhibit No. |
Description | |
| Exhibit 99.1 | Press release dated January 17, 2017: SuliquaTM Approved in the European Union for the Treatment of Adults with Type 2 Diabetes | |
| Exhibit 99.2 | Press release dated January 30, 2017: Sanofi Appoints Kathleen Tregoning to Executive Committee and Executive Vice President, External Affairs | |
| Exhibit 99.3 | Press release dated February 1, 2017: Sanofi and Regeneron Announce First Approval of KevzaraTM (sarilumad) for the Treatment of Moderately to Severely Active Rheumatold Arthritis in Adult Patients by Health Canada | |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Dated: February 1, 2017 | SANOFI | |||||
| By | /s/ Alexandra Roger | |||||
| Name: | Alexandra Roger | |||||
| Title: | Head of Securities Law and Capital Markets | |||||
3
| Exhibit No. |
Description | |
| Exhibit 99.1 | Press release dated January 17, 2017: SuliquaTM Approved in the European Union for the Treatment of Adults with Type 2 Diabetes | |
| Exhibit 99.2 | Press release dated January 30, 2017: Sanofi Appoints Kathleen Tregoning to Executive Committee and Executive Vice President, External Affairs | |
| Exhibit 99.3 | Press release dated February 1, 2017: Sanofi and Regeneron Announce First Approval of KevzaraTM (sarilumad) for the Treatment of Moderately to Severely Active Rheumatold Arthritis in Adult Patients by Health Canada | |
4
| This ‘6-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / For Period End: | 2/1/17 | None on these Dates | ||
| 1/30/17 | ||||
| 1/17/17 | ||||
| List all Filings | ||||